Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its investigational ...
In an interview with Targeted Oncology, Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center, ...
AVC-203 is the world's first CRISPR-engineered allogeneic dual-targeting CD19/CD20 switchable CAR-T cell therapy to enter clinical testing WATERTOWN, Mass., April 2, 2026 /PRNewswire/ -- AvenCell ...
MINNEAPOLIS, March 11, 2025 /PRNewswire/ — Luminary Therapeutics today announced that it has been awarded up to $5.8 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), ...
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful cell therapy—Legend ...
Qihan Biotech, a biotechnology company dedicated to applying high-throughput, multiplexed gene editing technologies to cell therapy and organ transplantation, announced today that QT-019C has received ...
BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug ...
Rising Cancer Cases, Technological Advancements, and Expanding CAR-T Applications Continue to Drive Global Market ...
SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results